Orthopedic Biologics Supplier in Albany, NY

Account Setup for Larger Orthopedic Groups

Albany's orthopedic provider base includes a number of larger multi-physician groups and surgery centers, which tend to centralize purchasing through a single practice manager even though each ordering physician's NPI is verified individually.

A group with several verified NPIs under one account can still track lot usage per clinician, which keeps patient-record-level traceability intact even when ordering is centralized.

Receiving Shipments in the Northeast

Cryopreserved Wharton's jelly product ships overnight on dry ice in a validated container and needs to go directly into -80 C storage on arrival; practices should have a staff member assigned to receive and log the shipment the same day it arrives rather than leaving it at a front desk.

Lyophilized Wharton's jelly and exosome formats skip the cold-chain step entirely and are stored according to the product insert included with that lot, which some practices find easier to manage around weekend or holiday deliveries.

Documentation Before the First Order

Before a new biologics line is added, most orthopedic practices request the certificate of analysis, the donor eligibility summary, and the lot release record showing that third-party sterility testing was complete before the lot was released from quarantine.

Surgery centers that stock product for scheduled procedures sometimes request these records in advance of the shipment date rather than waiting for them to arrive with the product.

Confirming Scope of Practice

Whether a specific intended use for a Wharton's jelly product fits within the applicable HCT/P framework is a determination the ordering physician makes with their own counsel, not something Precision Biologics certifies. New York practices should confirm license status and scope of practice with the New York State medical board before adding a new biologics category.

Account setup includes a peer-to-peer call focused on reviewing documentation; it is not a substitute for that legal and regulatory review.

FDA has stated there are no FDA-approved exosome products. Exosome products are generally regulated as biologic drugs under section 351 of the Public Health Service Act, not as 361 HCT/Ps. Purchase and clinical use decisions belong to the physician with their own regulatory counsel.

These products are not FDA approved or licensed for any disease or condition. Information is for licensed healthcare professionals and is not medical or legal advice.